azn201404246k3.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2014

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________

 

 


ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2014

Results of Annual General Meeting held on 24 April 2014

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 9 and 13 were passed as ordinary resolutions and resolutions 10 - 12 were passed as special resolutions.
 
 
RESOLUTION
VOTES FOR
% OF VOTES CAST
VOTES AGAINST
% OF VOTES CAST
VOTES CAST IN TOTAL
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
VOTES WITHHELD
1
To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2013
870,033,204
97.89
18,778,918
2.11
888,812,122
70.46%
11,139,925
2
To confirm dividends
893,931,728
99.57
3,902,685
0.43
897,834,413
71.17%
2,117,634
3
To appoint KPMG LLP, London as Auditor
876,625,428
98.63
12,214,852
1.37
888,840,280
70.46%
11,111,767
4
To authorise the Directors to agree the remuneration of the Auditor
893,579,679
99.54
4,118,441
0.46
897,698,120
71.16%
2,253,927
5a
To re-elect Leif Johansson as a Director
889,965,734
99.14
7,676,973
0.86
897,642,707
71.16%
2,309,340
5b
To re-elect Pascal Soriot as a Director
897,134,446
99.96
371,409
0.04
897,505,855
71.15%
2,446,192
5c
To elect Marc Dunoyer as a Director
889,628,471
99.12
7,871,986
0.88
897,500,457
71.15%
2,451,590
5d
To re-elect Geneviève Berger as a Director
896,973,595
99.94
537,923
0.06
897,511,518
71.15%
2,440,529
5e
To re-elect Bruce Burlington as a Director
897,004,578
99.95
479,515
0.05
897,484,093
71.15%
2,467,954
5f
To elect Ann Cairns as a Director.
897,096,680
99.95
434,031
0.05
897,530,711
71.15%
2,421,336
5g
To re-elect Graham Chipchase as a Director
895,582,520
99.79
1,906,668
0.21
897,489,188
71.15%
2,462,859
5h
To re-elect Jean-Philippe Courtois as a Director
507,689,816
56.97
383,431,429
43.03
891,121,245
70.64%
8,830,801
5i
To re-elect Rudy Markham as a Director
883,555,362
98.45
13,948,771
1.55
897,504,133
71.15%
2,447,914
5j
To re-elect Nancy Rothwell as a Director
866,230,058
96.51
31,324,104
3.49
897,554,162
71.15%
2,397,885
5k
To re-elect Shriti Vadera as a Director
890,107,349
99.17
7,412,193
0.83
897,519,542
71.15%
2,432,505
5l
To re-elect John Varley as a Director.
865,725,412
96.46
31,781,043
3.54
897,506,455
71.15%
2,445,592
5m
To re-elect Marcus Wallenberg as a Director.
794,350,592
89.19
96,276,858
10.81
890,627,450
70.60%
9,324,597
6
To approve the Annual Report on Remuneration for the year ended 31 December 2013
546,233,371
61.46
342,504,005
38.54
888,737,376
70.45%
11,214,670
7
To approve the Directors' Remuneration Policy
623,298,717
85.00
110,030,311
15.00
733,329,028
58.13%
166,623,018
8
To authorise limited EU political donations
869,296,180
97.48
22,506,342
2.52
891,802,522
70.70%
8,149,525
9
To authorise the Directors to allot shares
802,973,415
89.68
92,408,410
10.32
895,381,825
70.98%
4,391,643
10
To authorise the Directors to disapply pre-emption rights
880,119,551
98.50
13,443,551
1.50
893,563,102
70.84%
6,388,945
11
To authorise the Company to purchase its own shares
896,314,664
99.85
1,320,394
0.15
897,635,058
71.16%
2,316,989
12
To reduce the notice period for general meetings
753,622,756
83.98
143,754,313
16.02
897,377,069
71.14%
2,574,978
13
To approve the AstraZeneca 2014 Performance Share Plan
835,615,520
93.66
56,608,840
6.34
892,224,360
70.73%
7,727,687




Issued capital
As at 22 April 2014, the number of issued shares of the Company was 1,261,461,150 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.


A C N Kemp
Company Secretary
24 April 2014
 

 
 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 24 April 2014
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary